Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | RORA | P35398 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | RORB | Q92753 | 1/20 | 0.33 |
| ▸ | PLK1 | P53350 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10128833 | 0.83 | TSPO (0.34) | MEN1KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL10128877 | 0.81 | POLB (0.41) | MEN1KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL10128868 | 0.78 | HTR2C (0.42) | MEN1KMT2AALDH1A1 | |
| SCHEMBL10128873 | 0.78 | GABRA1 (0.34) | MEN1KMT2AALDH1A1POLBRORA | |
| SCHEMBL10128881 | 0.76 | POLB (0.50) | ALDH1A1SMN1; SMN2POLBGABRG2GABRB3 | |
| SCHEMBL10128679 | 0.76 | POLB (0.42) | MEN1KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL10128891 | 0.75 | POLB (0.39) | POLB | |
| SCHEMBL10128887 | 0.74 | POLB (0.48) | ALDH1A1SMN1; SMN2POLBGABRG2GABRB3 | |
| SCHEMBL10128714 | 0.74 | POLB (0.41) | MEN1KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL10128892 | 0.73 | POLB (0.44) | MEN1KMT2AALDH1A1SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034486-B2 | Triazole derivative, heterocyclic compound, light-emitting element, light-emitting device, electronic device and lighting device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD (JP) | 2015-05-19 | — | — | US | disclosed |
| US-9034486-B2 | Triazole derivative, heterocyclic compound, light-emitting element, light-emitting device, electronic device and lighting device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD (JP) | 2015-05-19 | — | — | US | disclosed |
| WO-2012017842-A1 | TRIAZOLE DERIVATIVE, HETEROCYCLIC COMPOUND, LIGHT-EMITTING ELEMENT, LIGHT-EMITTING DEVICE, ELECTRONIC DEVICE AND LIGHTING DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2012-02-09 | — | — | WO | disclosed |
| US-20120025697-A1 | Triazole Derivative, Heterocyclic Compound, Light-Emitting Element, Light-Emitting Device, Electronic Device and Lighting Device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. | 2012-02-02 | — | — | US | disclosed |
| US-20120025697-A1 | Triazole Derivative, Heterocyclic Compound, Light-Emitting Element, Light-Emitting Device, Electronic Device and Lighting Device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120025697-A1 | Triazole Derivative, Heterocyclic Compound, Light-Emitting Element, Light-Emitting Device, Electronic Device and Lighting Device | HTR3D, KCNQ4, KCNQ3 | MEN1 3598/4885KMT2A 1074/4885ALDH1A1 1032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.